Analyzing Predictive Technology Group (OTCMKTS:PRED) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

Predictive Technology Group (OTCMKTS:PRED) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Institutional and Insider Ownership

8.0% of 60 Degrees Pharmaceuticals shares are held by institutional investors. 1.7% of 60 Degrees Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Predictive Technology Group and 60 Degrees Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Technology Group	N/A	N/A	N/A	N/A	N/A
60 Degrees Pharmaceuticals	$1.41 million	2.13	-$7.36 million	($8.92)	-0.13

Predictive Technology Group has higher earnings, but lower revenue than 60 Degrees Pharmaceuticals.

Volatility & Risk

Predictive Technology Group has a beta of -0.77, meaning that its share price is 177% less volatile than the S&P 500. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.54, meaning that its share price is 154% more volatile than the S&P 500.

Profitability

This table compares Predictive Technology Group and 60 Degrees Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Predictive Technology Group	N/A	N/A	N/A
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Predictive Technology Group and 60 Degrees Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Technology Group	0	0	0	0	0.00
60 Degrees Pharmaceuticals	1	2	1	0	2.00

60 Degrees Pharmaceuticals has a consensus price target of $13.85, suggesting a potential upside of 1,125.66%. Given 60 Degrees Pharmaceuticals’ stronger consensus rating and higher possible upside, analysts plainly believe 60 Degrees Pharmaceuticals is more favorable than Predictive Technology Group.

Summary

60 Degrees Pharmaceuticals beats Predictive Technology Group on 7 of the 9 factors compared between the two stocks.

About Predictive Technology Group

Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditions; and regenerative medicine products, including AmnioCyte, AmnioCyte Plus, PolyCyte, and CoreCyte for use in regenerative medicine applications. It has a collaboration agreement with Atrin Pharmaceuticals LLC to develop molecular diagnostic tools to facilitate enhanced selection of cancer patients. The company was formerly known as Global Enterprises Group, Inc. and changed its name to Predictive Technology Group, Inc. in July 2015. Predictive Technology Group, Inc. was founded in 2005 and is headquartered in Salt Lake City, Utah. On November 9, 2023, Predictive Technology Group, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Utah. On January 12, 2024, the voluntary petition of Predictive Technology Group, Inc. for reorganization under Chapter 11 was converted to Chapter 7. It had filed for Chapter 11 bankruptcy on November 9, 2023.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.